Screening and treatment for Alzheimer's disease: Predicting population-level outcomes

Alzheimer's and Dementia

Volumn 8, Issue 1, 2012, Pages 31-38

  Furiak, Nicolas M ^a   Kahle Wrobleski, Kristin ^b   Callahan, Christopher ^c   Klein, Timothy M ^a   Klein, Robert W ^a   Siemers, Eric R ^b  

^a Medical Decision Modeling Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Dementia; Modeling; Policy; Screening; Simulation

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; DEMENTIA; DRUG EFFICACY; HUMAN; MASS SCREENING; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MASS SCREENING; MENTAL STATUS SCHEDULE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84855998856     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.05.2415     Document Type: Article

References (31)

1. L.E. Hebert, P.A. Scherr, J.L. Bienias, D.A. Bennett, and D.A. Evans Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch Neurol 60 2003 1119 1122 (Pubitemid 36975801)
2. Alzheimer's Association. Facts and Figures, 2010; cited October 29, 2010. Available at: http://www.alz.org/alzheimers-disease-facts-figures.asp.
3. R. Sperling, P. Aisen, L. Beckett, D. Bennett, S. Craft, and A. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 280 292
4. M. Albert, S. DeKosky, D. Dickson, B. Dubois, H. Feldman, and N. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup Alzheimers Dement 7 2011 270 279
5. G. McKhann, D. Knopman, H. Chertkowd, B. Hyman, C. Jack, and C. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 263 269
6. K. Blennow, and H. Zetterberg Pinpointing plaques with PIB Nat Med 12 2006 753 754 discussion 754 (Pubitemid 44050055)
7. C.R. Jack, D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, R.C. Petersen, and J.Q. Trojanowski Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
8. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944 (Pubitemid 14076461)
9. E.M. Reiman, J.B. Langbaum, and P.N. Tariot Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible Biomark Med 4 2010 3 14
10. A.M. Fagan, C.A. Csernansky, J.C. Morris, and D.M. Holtzman The search for antecedent biomarkers of Alzheimer's disease J Alzheimers Dis 8 2005 347 358
11. C. Hassan, E. Di Giulio, P.J. Pickhardt, A. Zullo, A. Laghi, D.H. Kim, F. Iafrate, and S. Morini Cost effectiveness of colonoscopy, based on the appropriateness of an indication Clin Gastroenterol Hepatol 6 2008 1231 1236
12. R.M. Ness, A.M. Holmes, R. Klein, and R. Dittus Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages Am J Gastroenterol 95 2000 1800 1811 (Pubitemid 30485022)
13. S. Subramanian, G. Bobashev, and R.J. Morris Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance Cancer Epidemiol Biomarkers Prev 18 2009 1971 1978
14. B. Levin, D.A. Lieberman, B. McFarland, K.S. Andrews, D. Brooks, and J. Bond Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology Gastroenterology 134 2008 1570 1595 (Pubitemid 351615355)
15. F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, and V. Nelen Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
16. D. Saslow, C. Boetes, W. Burke, S. Harms, M.O. Leach, and C.D. Lehman American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography CA Cancer J Clin 57 2007 75 89 (Pubitemid 46535708)
17. C.J. Baines Are there downsides to mammography screening? Breast J 11 Suppl 1 2005 S7 10
18. P.C. Allgood, S.W. Duffy, R. Warren, and G. Hunnam Audit of negative assessments in a breast-screening programme in women who later develop breast cancer-implications for survival Breast 15 2006 503 509 (Pubitemid 44109121)
19. A.N. Kleit, and J.F. Ruiz False positive mammograms and detection controlled estimation Health Serv Res 38 2003 1207 1228 (Pubitemid 37048307)
20. S. Ciatto, N. Houssami, D. Ambrogetti, R. Bonardi, G. Collini, and M.R. Del Turco Minority report-false negative breast assessment in women recalled for suspicious screening mammography: imaging and pathological features, and associated delay in diagnosis Breast Cancer Res Treat 105 2007 37 43 (Pubitemid 47282742)
21. K. Armstrong, E. Moye, S. Williams, J.A. Berlin, and E.E. Reynolds Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians Ann Intern Med 146 2007 516 526 (Pubitemid 351650561)
22. J.S. Mandelblatt, C.B. Schechter, K.R. Yabroff, W. Lawrence, J. Dignam, and M. Extermann Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status J Gen Intern Med 20 2005 487 496 (Pubitemid 41007065)
23. R. Brookmeyer, S. Gray, and C. Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1998 1337 1342 (Pubitemid 28402270)
24. N.M. Furiak, R.W. Klein, K. Kahle-Wrobleski, E.R. Siemers, E. Sarpong, and T.M. Klein Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model BMC Med Inform Decis Mak 10 2010 24
25. A. Beiser, R.B. D'Agostino, S. Seshadri, L.M. Sullivan, and P.A. Wolf Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro Stat Med 19 2000 1495 1522 (Pubitemid 30346242)
26. S. Seshadri, P.A. Wolf, A. Beiser, R. Au, K. McNulty, R. White, and R.B. D'Agostino Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study Neurology 49 1997 1498 1504 (Pubitemid 28015107)
27. R.C. Petersen Mild cognitive impairment as a diagnostic entity J Intern. Med 256 2004 183 194 (Pubitemid 39222988)
28. T.I. Barron, R. Connolly, K. Bennett, J. Feely, and M.J. Kennedy Early discontinuation of tamoxifen: a lesson for oncologists Cancer 109 2007 832 839 (Pubitemid 46333524)
29. R.S. Doody, S.H. Ferris, S. Salloway, Y. Sun, R. Goldman, W.E. Watkins, Y. Xu, and A.K. Murthy Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial Neurology 72 2009 1555 1561
30. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
31. P.D. Sloane, S. Zimmerman, C. Suchindran, P. Reed, L. Wang, M. Boustani, and S. Sudha The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances Annu Rev Public Health 23 2002 213 231 (Pubitemid 34508073)